A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants.

Trial Profile

A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary) ; Pneumococcal vaccine conjugate; Typhoid vaccine Vi-polysaccharide
  • Indications Pneumococcal infections; Typhoid
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 21 Mar 2012 Additional trial location (Italy) added as reported by Clinical Trials Registry - India.
    • 21 Mar 2012 Additional lead trial centre and investigator identified as reported by Clinical Trials Registry - India.
    • 18 Jan 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2011-12-002233).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top